/sup 125/I therapy in Graves' disease. Long-term results in 355 patients
Journal Article
·
· Ann. Intern. Med.; (United States)
Because of the physical and radiobiologic differences between /sup 125/I and /sup 131/I, a trial using /sup 125/I to treat hyperthyroidism was undertaken in the hope of controlling hyperthyroidism without causing subsequent hypothyroidism. Three hundred fifty-five patients with diffuse toxic goitres were treated and have been under review for an average of 49.4 months: 63.4 percent are euthyroid, 33.5 percent are hypothyroid, and 3.1 percent remain hyperthyroid. Different groups of patients received a wide range of doses of /sup 125/I (4.0 to 56.0 mCi), and the lowest incidence of hypothyroidism (23 percent) was in the group that received between 6.0 and 10.5 mCi. Sixty-three percent of the patients whose initial dose was greater than 20.0 mCi are hypothyroid. Persistent hyperthyroidism was common in patients who received small doses. Because of the high incidence of posttreatment hypothyroidism in this series and because /sup 131/I has stood the test of time, we believe that /sup 131/I is the radionuclide of choice for the routine treatment of hyperthyroidism.
- Research Organization:
- Royal Infirmary, Glasgow
- OSTI ID:
- 7306688
- Journal Information:
- Ann. Intern. Med.; (United States), Journal Name: Ann. Intern. Med.; (United States) Vol. 85:6; ISSN AIMEA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Early results of $sup 125$I therapy of thyrotoxic Graves' disease
Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine
RADIOACTIVE IODINE IN THE TREATMENT OF HYPERTHYROIDISM (EXPERIENCE AT THE TORONTO GENERAL HOSPITAL, 1950-58). PART III. POSSIBLE BIOLOGICAL HAZARDS FROM RADIOACTIVE IODINE THERAPY
Journal Article
·
Mon Apr 01 00:00:00 EDT 1974
· J. Nucl. Med., v. 15, no. 4, pp. 257-260
·
OSTI ID:4331393
Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine
Journal Article
·
Mon Dec 31 23:00:00 EST 1990
· Journal of Nuclear Medicine; (USA)
·
OSTI ID:6059074
RADIOACTIVE IODINE IN THE TREATMENT OF HYPERTHYROIDISM (EXPERIENCE AT THE TORONTO GENERAL HOSPITAL, 1950-58). PART III. POSSIBLE BIOLOGICAL HAZARDS FROM RADIOACTIVE IODINE THERAPY
Journal Article
·
Fri Jan 13 23:00:00 EST 1961
· Canadian Medical Association Journal (Canada)
·
OSTI ID:4105579
Related Subjects
560161* -- Radionuclide Effects
Kinetics
& Toxicology-- Man
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
BETA DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
ENDOCRINE DISEASES
ENDOCRINE GLANDS
GLANDS
HYPERTHYROIDISM
HYPOTHYROIDISM
INTERMEDIATE MASS NUCLEI
IODINE 125
IODINE ISOTOPES
ISOTOPES
MEDICINE
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PATIENTS
RADIATION EFFECTS
RADIOINDUCTION
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SIDE EFFECTS
THERAPY
THYROID
Kinetics
& Toxicology-- Man
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
BETA DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
ENDOCRINE DISEASES
ENDOCRINE GLANDS
GLANDS
HYPERTHYROIDISM
HYPOTHYROIDISM
INTERMEDIATE MASS NUCLEI
IODINE 125
IODINE ISOTOPES
ISOTOPES
MEDICINE
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PATIENTS
RADIATION EFFECTS
RADIOINDUCTION
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SIDE EFFECTS
THERAPY
THYROID